PMID- 31002184
OWN - NLM
STAT- MEDLINE
DCOM- 20200106
LR  - 20210109
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 33
IP  - 6
DP  - 2019 Jul
TI  - ESRRG promoter hypermethylation as a diagnostic and prognostic biomarker in 
      laryngeal squamous cell carcinoma.
PG  - e22899
LID - 10.1002/jcla.22899 [doi]
LID - e22899
AB  - BACKGROUND: Estrogen-related receptor gamma (ESRRG) has been identified as a 
      tumor suppressor gene in several cancers. We aimed to evaluate ESRRG promoter 
      methylation in laryngeal squamous cell carcinoma (LSCC) and its relative clinical 
      value in LSCC. METHODS: Bisulfite pyrosequencing assays were performed on 91 
      pairs of tumor and paracancer tissues from LSCC patients in China. The diagnostic 
      value and overall survival (OS) were analyzed descriptively by receiver operating 
      characteristic (ROC) curves and the Kaplan-Meier methods, respectively. RESULTS: 
      The ESRRG promoter was more frequently hypermethylated in tumor tissues than in 
      adjacent tissues (P < 0.01). ESRRG promoter methylation was significantly 
      increased in advanced T stage tumors (P < 0.01) and advanced clinical stage 
      patients (P < 0.01). Moreover, the area under the ROC curve (AUC) value (0.81) 
      indicated high discrimination accuracy. Furthermore, ESRRG hypermethylation was 
      associated with poor OS, as confirmed by Kaplan-Meier survival curves (P < 0.01). 
      CONCLUSION: Our study indicated that ESRRG promoter hypermethylation contributed 
      to LSCC-related risks, primarily tumor progression and survival prognosis, in 
      patients. ESRRG promoter methylation could, therefore, be a diagnostic and 
      prognostic biomarker in LSCC.
CI  - (c) 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley 
      Periodicals, Inc.
FAU - Shen, Zhisen
AU  - Shen Z
AUID- ORCID: 0000-0001-6660-0488
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University, Ningbo, China.
FAU - Hu, Yan
AU  - Hu Y
AD  - Department of Otolaryngology, Ningbo University Medical School, Ningbo, China.
FAU - Zhou, Chongchang
AU  - Zhou C
AUID- ORCID: 0000-0002-8728-6819
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University, Ningbo, China.
FAU - Yuan, Jie
AU  - Yuan J
AD  - Department of Otolaryngology, Ningbo University Medical School, Ningbo, China.
FAU - Xu, Jie
AU  - Xu J
AD  - Department of Otolaryngology, Ningbo University Medical School, Ningbo, China.
FAU - Hao, Wenjuan
AU  - Hao W
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University, Ningbo, China.
FAU - Deng, Hongxia
AU  - Deng H
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University, Ningbo, China.
FAU - Ye, Dong
AU  - Ye D
AUID- ORCID: 0000-0003-2055-0256
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Lihuili Hospital of 
      Ningbo University, Ningbo, China.
LA  - eng
GR  - NBLJ201801032/Leading and Top Talents Training Projects of Ningbo/
GR  - 2015RCB025/Medical and Health Training Project of Zhejiang Province/
GR  - PPXK2018-02/Ningbo Health Branding Subject Fund/
GR  - LY14H160003, No.LH19H160014/Zhejiang Provincial Natural Science Foundation of 
      China/
GR  - 2012B82019/Scientific Innovation Team Project of Ningbo/
GR  - 2012C5015/Ningbo Social Developmental Key Research Project/
GR  - 2012ZDA042/Medical and Health Research Project of Zhejiang Province/
GR  - 2014PYA017/Medical and Health Research Project of Zhejiang Province/
GR  - 2018RC063/Medical and Health Research Project of Zhejiang Province/
GR  - 2019ZD018/Medical and Health Research Project of Zhejiang Province/
PT  - Journal Article
DEP - 20190419
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (ESRRG protein, human)
RN  - 0 (Receptors, Estrogen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics
MH  - Carcinoma, Squamous Cell/*genetics/mortality/pathology
MH  - *DNA Methylation
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/*genetics/mortality/pathology
MH  - Middle Aged
MH  - Prognosis
MH  - *Promoter Regions, Genetic
MH  - ROC Curve
MH  - Receptors, Estrogen/*genetics
PMC - PMC6642328
OTO - NOTNLM
OT  - DNA methylation
OT  - diagnostics
OT  - estrogen-related receptor gamma
OT  - laryngeal squamous cell carcinoma
OT  - prognostics
EDAT- 2019/04/20 06:00
MHDA- 2020/01/07 06:00
PMCR- 2019/04/19
CRDT- 2019/04/20 06:00
PHST- 2019/01/18 00:00 [received]
PHST- 2019/02/22 00:00 [revised]
PHST- 2019/03/21 00:00 [accepted]
PHST- 2019/04/20 06:00 [pubmed]
PHST- 2020/01/07 06:00 [medline]
PHST- 2019/04/20 06:00 [entrez]
PHST- 2019/04/19 00:00 [pmc-release]
AID - JCLA22899 [pii]
AID - 10.1002/jcla.22899 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2019 Jul;33(6):e22899. doi: 10.1002/jcla.22899. Epub 2019 Apr 
      19.